InnoCare Pharma’s Post

IACH News of the week 15 | Sep | 2024 International Academy for Clinical Hematology (IACH) Mohamad Mohty Here are the latest hematology updates (including reviews, clinical trials, non-experimental studies, guidelines, among others).

HemaTopics are HemaSphere publications focusing on hot hematology topics including recent research developments, updates on diagnosis and treatment, policy and guidelines news, and more. This week we focus on the latest HemaTopic by Scientific Editor Charles de Bock which discusses a recent study from the Ross Levine Lab, which provides a strong rationale for the ongoing development of more potent JAK2 inhibitors. https://bit.ly/43KMqWP

What diseases can be indicated by the results from a hematology analyzer? Here are a few examples: #hematologyanalyzer #LIFOTRONIC #CBC #AC310 #AC610 #AC630

How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0

New publication 📝 Retrospective analysis published in Hematology provides new insights for #AcuteLymphoblasticLeukemia, see: https://loom.ly/vnLhcDM #ALLsm #leusm #MedEducation

Nucleic acid therapeutics are currently the third major drug class after small molecule and antibodies, and are expected to keep gaining momentum in the near future. The current article provides an elegant review of the challenging history of the field, milestones and anticipated innovation. With the promise of reaching organs previously inaccessible to the field, different nucleic acid therapeutic modalities are currently investigated in 80 clinical trials- mainly 20 for liver targets, 10 for CNS targets, 10 for oncological targets, and others in the muscle, skin, lung, eye, or placenta. Link: https://lnkd.in/e7idfQXZ #RNAi #siRNA #ASO #oligonucleotides #CRISPR #aptamers

Have you read our recent Q&A with our Reach-the-World Fellow Mark Allan Lim? Learn more about his interest in improving the field of hematology in the Philippines here: https://lnkd.in/eqecTerN

One single EDTA tube for all whole blood analysis. Complete automation from sample collection to analysis to result reporting.   Discover how Mindray CAL 8000 All-in-One Hematology Solution is pushing hematology automation to new heights. Dive deeper at: https://lnkd.in/dqyZwmWx   #MindrayAllinOneSolution #MindrayHematology #LaboratoryAutomation #HematologyAutomation   

When it comes to hematology the right diagnosis and the right treatment are critical. GTC's Hematology profile Plus and Liquid trace can help nail the diagnosis. Learn more:https://lnkd.in/gBmGD6u #GenomicTestingCooperative

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology